Organic Active Ingredients TRIZ Cases

Pyrrolo-pyridine compounds inhibit multiple VEGF kinases simultaneously, resolving insufficient tumor suppression in current therapies.

Pyridine sulfonamides selectively target Nav 1.7 channels, resolving the trade-off between clinical efficacy and harmful side effects on non-pain pathways.

Copper pyrithione complexes traverse fungal mitochondrial membranes to inhibit aconitase activity.

Reducing resistant potato starch concentration to 0.1-2.5% treats post-weaning diarrhea while avoiding antibiotic resistance and environmental contamination.

A topical formulation delivers a JAK3 inhibitor to treat cutaneous lupus lesions while avoiding systemic side effects.

Phosphatidylcholine lipid formulations enable transdermal delivery of finasteride and minoxidil, bypassing oral administration to reduce systemic side effects.

Extended release calcifediol capsules maintain therapeutic serum concentrations to reduce viral load and severity where prior agents failed.

A self-inactivating lentiviral transfer system delivers multiple therapeutic molecules via a helper construct lacking functional packaging signals.

Formula I aminopyrazole compounds selectively inhibit JAK-1 to treat atopic dermatitis in young animals without severe adverse effects.

Combining linseed and xanthan gums yields a nature-identical lubricant that solves inadequate viscosity and poor mucosal adhesion in personal care applications.

Cyclic dinucleotide analogs overcome drug resistance and tolerability issues by enhancing immune response against chronic hepatitis B infection.

Retinoid-liposomes transport siRNA to hepatic stellate cells, suppressing HSP47 expression and collagen production.

Synthesized pyridine derivatives inhibit Factor Xa to prevent thrombosis.

Optimized acid ratios reduce waste and enable direct filtration.

Modified nucleosides reduce cellular toxicity while maintaining antiviral efficacy against resistant HIV strains.

Stereoisomeric compounds inhibit 5-oxoprolinase, blocking glutathione synthesis and tumor progression while minimizing toxicity to normal cells.

Nanoparticle-delivered LDHC silencing induces genomic instability in cancer cells, sensitizing them to DNA damaging drugs and PARP inhibitors.

Anti-CGRP antibodies bind specifically to the CGRP receptor to inhibit molecular interactions, reducing adverse side effects from elevated CGRP levels.

Novel biaryl amide compounds bind Raf kinases in a DFG-out mode, preventing paradoxical MAPK pathway activation.

mDia agonists disrupt tumor microtube formation, halting glioma invasion and overcoming chemoresistance.

Uronic feedstocks inhibit antibiotic inactivation pathways and decrease NADH production, reducing required antibiotic concentrations.

Novel glycyrrhetinic acid derivatives act as PPARγ agonists to induce specificity protein degradation in cancer cells.

A non-aqueous chitosan and alginate composition forms a polyelectrolyte gel upon injection to seal diseased blood vessels.

A spiraling ballistic projectile injection system delivers sedative formulations at distance using inertial rotation.

Condensed heterocyclic compounds with cross-linked amine structures inhibit JAK3 to treat autoimmune and inflammatory diseases.

Combining Everolimus with the Bcl-2 inhibitor ABT-737 targets mTOR signaling and induces apoptosis in renal cell carcinoma cells.

RANK/RANKL antagonists block osteoclast differentiation, addressing inadequate pain relief from conventional treatments that ignore bone resorption mechanisms.

Pharmaceutical composition maintains fulvestrant solubility using ethanol and polyhydric alcohols to prevent injection site precipitation.

A pharmaceutical composition uses a cyclodextrin derivative to form an inclusion complex with prasugrel, enhancing drug solubility and bioavailability.

Trifluridine and tipiracil hydrochloride combination drug paired with anti-VEGF antibodies to enhance antitumor efficacy.

A creatine gummy formulation uses a gel matrix to encapsulate the supplement and mask its bitter taste.

Salt-free beta-hydroxybutyrate formulations resolve the contradiction between effective ketosis promotion and harmful side effects from excessive sodium intake.

Optimized pyrimidinone derivatives resolve the trade-off between high potency and inhalation developability for respiratory disease treatment.

Synthesizing C5aR antagonists via stereoselective steps to eliminate enantiomeric impurities.

A DNA vaccine uses perforin to induce necrosis and stimulate CD4+ and CD8+ T cell responses.

Prodrug depot formulations extend the duration of drug effect to resolve patient compliance issues caused by frequent dosing requirements.

siRNA silences PRDX5 and GPX4 to overcome androgen deprivation therapy resistance, reducing tumor progression.

Lyophilized glycosaminoglycans reduce hyaluronic acid viscosity, enabling easier injection and stable storage of high molecular weight formulations.

Small molecule compositions reprogram non-cardiac cells into functional cardiomyocytes, eliminating mutation risks from genetic manipulation.

Anti-TGFβ antibody targets pathogenic TGFβ signaling to improve bone mineral density and reduce turnover, addressing inconsistent bisphosphonate effects.

Tryptophan, threonine, methionine, and isoleucine regulate food intake to address anorexia and obesity without addiction risks.

Plasminogen therapy dissolves pathogenic protein aggregates, protecting undamaged neurons and slowing disease progression in Huntington's models.

Eliminating glycerol from the base liquid reduces aerosol visibility while maintaining nicotine retention in the respiratory tract.

Segmented fused ring derivatives target the KRAS G12D mutation to provide therapeutic options for pancreatic and lung cancers.

High-purity eicosapentaenoic acid ethyl ester composition overcomes insufficient triglyceride reduction in existing therapies.

Inhaled crystalline particulates achieve high lung concentrations while maintaining low plasma levels to reduce systemic toxicity.

Antisense oligonucleotides inhibit SRp30c binding to glucocorticoid receptor pre-mRNA via complementary base pairing.

Topical lipogel merges lidocaine with diclofenac to extend pain relief duration while eliminating catheter-related infection risks.